Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future

Zhengyang Zhu; Chaoyou Fang; Houshi Xu; Ling Yuan; Yichao Du; Yunjia Ni; Yuanzhi Xu; Anwen Shao; Anwen Shao; Anke Zhang; Anke Zhang; Meiqing Lou

doi:10.3389/fonc.2022.976557

Frontiers in Oncology (Aug 2022)

Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future

Zhengyang Zhu,
Chaoyou Fang,
Houshi Xu,
Ling Yuan,
Yichao Du,
Yunjia Ni,
Yuanzhi Xu,
Anwen Shao,
Anwen Shao,
Anke Zhang,
Anke Zhang,
Meiqing Lou

Affiliations

Zhengyang Zhu: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Chaoyou Fang: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Houshi Xu: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Ling Yuan: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yichao Du: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yunjia Ni: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yuanzhi Xu: Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
Anwen Shao: Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Anwen Shao: Department of Neurosurgery, Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, China
Anke Zhang: Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Anke Zhang: Department of Neurosurgery, Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, China
Meiqing Lou: Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

DOI: https://doi.org/10.3389/fonc.2022.976557
Journal volume & issue: Vol. 12

Abstract

Read online

Glioma is the most common malignant intracranial tumor and exhibits diffuse metastasis and a high recurrence rate. The invasive property of glioma results from cell detachment. Anoikis is a special form of apoptosis that is activated upon cell detachment. Resistance to anoikis has proven to be a protumor factor. Therefore, it is suggested that anoikis resistance commonly occurs in glioma and promotes diffuse invasion. Several factors, such as integrin, E-cadherin, EGFR, IGFR, Trk, TGF-β, the Hippo pathway, NF-κB, eEF-2 kinase, MOB2, hypoxia, acidosis, ROS, Hsp and protective autophagy, have been shown to induce anoikis resistance in glioma. In our present review, we aim to summarize the underlying mechanism of resistance and the therapeutic potential of these molecules.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords